CytRx Corporation (CYTR)

0.37
0.01 2.78
NASDAQ
Prev Close 0.36
Open 0.35
Day Low/High 0.34 / 0.38
52 Wk Low/High 0.26 / 1.27
Volume 137.87K
Exchange NASDAQ
Shares Outstanding 33.64B
Market Cap 11.35M
Div & Yield N.A. (N.A)

Latest News

CytRx Corporation To Commence Trading On OTCQB Venture Market

CytRx Corporation To Commence Trading On OTCQB Venture Market

Company to Continue Trading Under Ticker Symbol "CYTR"

CytRx Corporation Reports First Quarter 2019 Financial Results

CytRx Corporation Reports First Quarter 2019 Financial Results

Out-licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High Unmet Need

CytRx Corporation Highlights Patent Issued For Use Of Aldoxorubicin In The Treatment Of Brain Cancer

CytRx Corporation Highlights Patent Issued For Use Of Aldoxorubicin In The Treatment Of Brain Cancer

The Patent Covers the Use of Aldoxorubicin Intravenously, Intra-Arterially or Intramuscularly for the Treatment of Brain Cancer

CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided By Licensee Orphazyme A/S

CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided By Licensee Orphazyme A/S

CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus Royalties, From Arimoclomol Licensing Agreement

CytRx Corporation Highlights Enrollment Completion In Phase 2/3 Clinical Trial Of Sporadic Inclusion Body Myositis Conducted By Arimoclomol Licensee Orphazyme A/S

CytRx Corporation Highlights Enrollment Completion In Phase 2/3 Clinical Trial Of Sporadic Inclusion Body Myositis Conducted By Arimoclomol Licensee Orphazyme A/S

CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus Royalties, From Arimoclomol Licensing Agreement

CytRx Corporation Reports 2018 Financial Results

CytRx Corporation Reports 2018 Financial Results

LADR™ Assets Well Aligned with Current Oncology Trends, Including Need for Improved Drugs and Potential for Combination with Immunotherapy

CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems

CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems

Novel Imaging Agent Would Enable Oncologists to Predict Which Patients Will Respond to Albumin-Binding Cytotoxic Treatment

CytRx Corporation Leads Revival Of Cytotoxic Therapies With LADR™ Technology Targeting Delivery Directly To The Tumor

CytRx Corporation Leads Revival Of Cytotoxic Therapies With LADR™ Technology Targeting Delivery Directly To The Tumor

LADR™ Scientific Research Published as Cover Story in the Peer Reviewed Journal of Controlled Release, a Leading Journal for Drug Delivery

CytRx Corporation Highlights Majority Of Cancer Patients Do Not Have Targetable Genetic Mutations And Are Therefore Candidates For Chemotherapy

CytRx Corporation Highlights Majority Of Cancer Patients Do Not Have Targetable Genetic Mutations And Are Therefore Candidates For Chemotherapy

Approximately 65% of Patients Do Not Have Targetable Genetic Mutations

Interesting CYTR Call Options For March 2018

Interesting CYTR Call Options For March 2018

Investors in CytRx Corp saw new options begin trading today, for the March 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Goodbye CytRx, Your Game Is Over

Goodbye CytRx, Your Game Is Over

Hope springs eternal, until it's dashed on the rocks and buried at sea.

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

First Week of CYTR September 15th Options Trading

First Week of CYTR September 15th Options Trading

Investors in CytRx Corp saw new options begin trading this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA

CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA

CytRx announced a plan Tuesday to seek U.S. marketing approval of aldoxorubicin based more on hocus-pocus than credible study results.

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.

24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation

24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation

Law Offices of Howard G. Smith reminds investors of the upcoming  September 23, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise...

GPM Reminds Investors Of The September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation And Encourages Investors To Contact The Firm

GPM Reminds Investors Of The September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") reminds investors of the September 23, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise...

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of CytRx Corporation ("CytRx" or the "Company") (NASDAQ:CYTR )...

CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016

CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased CytRx Corporation (NASDAQ:CYTR) securities...

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased CytRx Corporation ("CytRx" or the "Company") (NASDAQ: CYTR) securities between...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of CytRx Corporation ("CytRx" or the "Company") (NASDAQ: CYTR) ...

Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Losses From Investment In CytRx Corporation To Contact The Firm

Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Losses From Investment In CytRx Corporation To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf...

CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016

CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased CytRx Corporation (NASDAQ:CYTR) securities...

TheStreet Quant Rating: D- (Sell)